Interstitial lung disease in systemic sclerosis (systemic scleroderma)
Authors:
Open Access
- 17 March 2021
- journal article
- review article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (1S) , 1-62
Abstract
In systemic sclerosis (SSc), interstitial lung disease (ILD) is common (>80%) and worsens the prognosis of the disease, but severe progressive damage develops only in 8–10% of cases. Interstitial changes in the lungs occur early (within the first 3–5 years of the disease). The histological manifestations are similar to those of idiopathic ILD.The main tool for screening and diagnosing of ILD associated with SSc is high-resolution computed tomography of the lungs, resulting data influence the choice of therapy. In most patients a relatively intact and stable forced vital capacity of the lungs is recorded for a long time, but the diffusion capacity of the lungs decreases early and steadily. Pulmonary functional tests have prognostic value.The choice of the optimal therapy for SSc with lung lesions is based on general disease activity (the severity of inflammation and fibrosis) and the its severity, rate of progression of the disease in general and the leading pathology – interstitial pneumonia (IP) – in particular. In patients with SSc and severe or progressive IP, treatment with mycophenolate mofetil (MMF), cyclophosphamide, nintedanib, or nintedanib in combination with MMF if appropriate, should be considered. If this therapy is ineffective, rituximab may be used.Keywords
This publication has 124 references indexed in Scilit:
- Predictive Value of Serial High‐Resolution Computed Tomography Analyses and Concurrent Lung Function Tests in Systemic SclerosisArthritis & Rheumatology, 2015
- Survival of Adults With Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort StudyArthritis & Rheumatology, 2015
- Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic SclerosisJAMA, 2014
- Prediction of Pulmonary Complications and Long‐Term Survival in Systemic SclerosisArthritis & Rheumatology, 2014
- Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo GroupArthritis & Rheumatism, 2011
- Predicting treatment outcomes and responder subsets in scleroderma‐related interstitial lung diseaseArthritis & Rheumatism, 2011
- A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaArthritis & Rheumatism, 2006
- Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US populationArthritis & Rheumatism, 2003
- Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvementArthritis & Rheumatism, 2003
- Severe restrictive lung disease in systemic sclerosisArthritis & Rheumatism, 1994